Shanghai Wd Pharmaceutical Co., Ltd.

This study tests an extended-release tablet containing carbidopa and levodopa (WD-1603) for people with early Parkinson's disease. The goal is to see if taking the medication three times daily improves motor symptoms and daily living better than a placebo. The trial involves 40 a…

This early-stage trial is testing whether a new extended-release version of the Parkinson's drug combination carbidopa/levodopa is absorbed into the body as intended. Healthy adult volunteers will receive different strengths of the new tablet and the standard tablet, under both f…